Please use this identifier to cite or link to this item:
http://repo.knmu.edu.ua/handle/123456789/23045
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rozhdestvenska, Anastasiia | - |
dc.contributor.author | Zhelezniakova, Natalia | - |
dc.date.accessioned | 2019-05-28T08:49:04Z | - |
dc.date.available | 2019-05-28T08:49:04Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Rozhdestvenska A. Kallistatin as a new non-invasive marker in patients with non-alcoholic fatty liver disease combined with hypertension / A. Rozhdestvenska, N. Zhelezniakova // Current and Emerging Diseases : Maltepe University International Student Congress, Maltepe University, Istanbul, Turkey, 16–17 May 2019. – Istanbul, 2019. – P. 58–59. | ru_RU |
dc.identifier.uri | https://repo.knmu.edu.ua/handle/123456789/23045 | - |
dc.description.abstract | Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). | ru_RU |
dc.language.iso | en | ru_RU |
dc.subject | NAFLD | ru_RU |
dc.subject | kallistatin | ru_RU |
dc.subject | hypertension | ru_RU |
dc.title | Kallistatin as a new non-invasive marker in patients with non-alcoholicfattyliver disease combined with hypertension | ru_RU |
dc.type | Thesis | ru_RU |
Appears in Collections: | Наукові роботи молодих вчених. Кафедра внутрішньої медицини № 1 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Rozhdestvenska A. (Kharkiv, Ukraine).docx | 15,78 kB | Microsoft Word XML | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.